When investors think of ASX healthcare stocks, a handful of names stand out as global leaders.
ResMed Inc. (ASX: RMD) is one of them. It is an ASX share that has quietly become a powerhouse in sleep and respiratory care.
With a track record of growth stretching decades, a massive addressable market, and an innovative product pipeline, ResMed has all the hallmarks of a stock that could keep rewarding investors for years to come.
Image source: Getty Images
A growing global health challenge
ResMed's primary focus is treating sleep apnoea. It is a condition affecting an estimated 1 billion people worldwide, the majority of whom remain undiagnosed. As awareness grows and treatment options expand, the company is positioned to capture significant demand.
It has also broadened its scope into digital health and software solutions, offering tools that help healthcare providers monitor patients and improve adherence. This adds a recurring revenue stream and builds stickiness into its business model.
Compounding through innovation
One of ResMed's biggest strengths is its ability to innovate. As mentioned above, its connected devices and cloud-based platforms make it easier for patients to manage conditions and for doctors to track outcomes. By layering data and technology onto traditional devices, ResMed has differentiated itself from competitors.
This innovation has also driven operating leverage, with profits growing faster than revenues in recent years. In addition, its strong free cash flow generation means that ResMed can reinvest in research and development, make acquisitions, and return capital to shareholders through dividends and buybacks.
A long-term winner on the ASX
Over the past decade, ResMed has delivered an average annual total return of nearly 20%. This far outpaces the broader ASX. That consistency is rare and has created significant wealth for shareholders.
For example, if you had invested $10,000 into this ASX stock 10 years ago, you would now be sitting on an investment worth approximately $60,000.
Looking ahead, management expects high single-digit revenue growth through to 2029, with margins expanding further. Combined with its strong balance sheet and disciplined capital allocation, ResMed looks well positioned to keep compounding over the long term.
Foolish takeaway
Few ASX stocks have the scale, resilience, and global growth runway of ResMed.
With its focus on a massive health problem, an expanding digital ecosystem, and a proven ability to innovate, it could be one of the best long-term opportunities on the ASX today.
For investors seeking growth, resilience, and exposure to healthcare, ResMed deserves serious consideration as a core portfolio holding.
